Skip to search formSkip to main contentSkip to account menu

omalizumab Injection [Xolair]

National Institutes of Health

Related topics

Related topics

3 relations
InjectionXolair

Narrower (1)

omalizumab 150 MG Injection [Xolair]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair®)
Omalizumab (Xolair®) is an anti‐IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective… 
2016
2016
P-PiXel: A 'real-life' evaluation of omalizumab use in asthmatic patients
Omalizumab (OMA) (Xolair ® ) is an anti-IgE monoclonal antibody indicated for the maintenance treatment of persistent severe… 
2007
2007
Praktische Aspekte der Anti-IgE-Behandlung: Patientenauswahl und Therapie-Monitoring
The anti-IgE antibody omalizumab (Xolair®) has been approved for the treatment of severe, persistent allergic asthma (Step 4) in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)